Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Thrombosis and Haemostasis

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 10605721
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.

  1999cited by this paper
• Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck.

  1999cited by this paper
• Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule.

  1999cited by this paper
• Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty.

  1999cited by this paper
• Identification of a Novel Recognition Sequence for Integrin αMβ2 within the γ-chain of Fibrinogen*

  1998cited by this paper
• Effects of beta3-integrin blockade (c7E3) on the response to angioplasty and intra-arterial stenting in atherosclerotic nonhuman primates.

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence.

  1998cited by this paper
• Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin.

  1998cited by this paper
• Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.

  1998cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

  1998cited by this paper
• Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells.

  1998cited by this paper
• Ligand recognition by the I domain-containing integrins

  1998cited by this paper
• Role of integrin alpha(v)beta3 in vascular biology.

  1998cited by this paper
• Endothelial and leukocyte adhesion molecules in inflammation and disease.

  1998cited by this paper
• Activation of αVβ3 on Vascular Cells Controls Recognition of Prothrombin

  1998cited by this paper
• Cation binding to the integrin CD11b I domain and activation model assessment.

  1998cited by this paper
• Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration.

  1998cited by this paper
• Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging.

  1998cited by this paper
• Two Functional States of the CD11b A-Domain: Correlations with Key Features of Two Mn2+-complexed Crystal Structures

  1998cited by this paper
• Adhesion of Activated Platelets to Endothelial Cells: Evidence for a GPIIbIIIa-dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), αvβ3 Integrin, and GPIbα

  1998cited by this paper
• Role of vitronectin and its receptors in haemostasis and vascular remodeling.

  1998cited by this paper
• Leukocyte-endothelium adhesion molecules in atherosclerosis.

  1998cited by this paper
• Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.

  1998cited by this paper
• Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes.

  1998cited by this paper
• Importance of platelets in neutrophil adhesion and vasoconstriction after deep carotid arterial injury by angioplasty in pigs.

  1997cited by this paper
• Leukocyte Crosstalk at the Vascular Wall

  1997cited by this paper
• A global view on the role of monocytes and platelets in atherogenesis.

  1997cited by this paper
• Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment.

  1997cited by this paper
• Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation.

  1997cited by this paper
• Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia.

  1997cited by this paper
• Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

  1997cited by this paper
• 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

  1997cited by this paper
• Implications of atomic-resolution structures for cell adhesion.

  1997cited by this paper
• Intimal hyperplasia after balloon injury is attenuated by blocking selectins.

  1997cited by this paper
• Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

  1997cited by this paper
• Perspectives series: cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis.

  1997cited by this paper
• Evidence that the integrin beta3 and beta5 subunits contain a metal ion-dependent adhesion site-like motif but lack an I domain.

  1997cited by this paper
• Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model.

  1997cited by this paper
• Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin.

  1997cited by this paper
• In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.

  1997cited by this paper
• Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

  1996cited by this paper
• Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.

  1996cited by this paper
• Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18.

  1996cited by this paper
• The pathophysiology of vascular obstruction in the sickle syndromes.

  1996cited by this paper
• Integrins and cancer.

  1996cited by this paper
• Activated platelets signal chemokine synthesis by human monocytes.

  1996cited by this paper
• Potential mechanisms promoting restenosis in diabetic patients.

  1996cited by this paper
• Role of platelets in restenosis after percutaneous coronary revascularization.

  1996cited by this paper
• Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets.

  1996cited by this paper
• Inhibition of plasma‐mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD‐containing peptides

  1996cited by this paper
• Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces.

  1996cited by this paper
• Identifying the Putative Metal Ion-dependent Adhesion Site in the β2 (CD18) Subunit Required for αLβ2 and αMβ2 Ligand Interactions*

  1996cited by this paper
• Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

  1996cited by this paper
• Increased neutrophil-platelet adhesion in patients with unstable angina.

  1996cited by this paper
• Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

  1996cited by this paper
• Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the beta 2 integrin CD11b/CD18.

  1996cited by this paper
• The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.

  1995cited by this paper
• The Molecular Basis of Platelet and Endothelial Cell Interaction with Neutrophils and Monocytes: Role of P-Selectin and the P-Selectin Ligand, PSGL-1

  1995cited by this paper
• Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?

  1995cited by this paper
• Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.

  1995cited by this paper
• Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18).

  1995cited by this paper
• Two conformations of the integrin A-domain (I-domain): a pathway for activation?

  1995cited by this paper
• Alpha-v beta-3 integrin expression in normal and atherosclerotic artery.

  1995cited by this paper
• Distinct ligand binding sites in the I domain of integrin alpha M beta 2 that differentially affect a divalent cation-dependent conformation.

  1995cited by this paper
• Adhesion of flowing leucocytes to immobilized platelets

  1995cited by this paper
• Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.

  1995cited by this paper
• Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition.

  1995cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• Glanzmann thrombasthenia: new insights from an historical perspective.

  1994cited by this paper
• Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells.

  1994cited by this paper
• Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

  1994cited by this paper
• Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.

  1994cited by this paper
• Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model).

  1994cited by this paper
• Leukocyte-endothelial adhesion molecules.

  1994cited by this paper
• Postischemic Administration of an Anti‐Mac‐1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats

  1994cited by this paper
• Clustering of vitronectin and RGD peptides on microspheres leads to engagement of integrins on the luminal aspect of endothelial cell membrane.

  1994cited by this paper
• Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA.

  1994cited by this paper
• Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.

  1994cited by this paper
• Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

  1994cited by this paper
• Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain.

  1994cited by this paper
• The I domain is a major recognition site on the leukocyte integrin Mac- 1 (CD11b/CD18) for four distinct adhesion ligands

  1993cited by this paper
• The structural motif glycine 190-valine 202 of the fibrinogen gamma chain interacts with CD11b/CD18 integrin (alpha M beta 2, Mac-1) and promotes leukocyte adhesion.

  1993cited by this paper
• Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.

  1993cited by this paper
• Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion.

  1993cited by this paper
• Coagulation assembly on leukocytes in transmembrane signaling and cell adhesion.

  1993cited by this paper
• Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway.

  1993cited by this paper
• The Platelet Glycoprotein IIb/IIIa Complex Is lnvolved in the Adhesion of Activated Platelets to Leukocytes

  1993cited by this paper
• Human endothelial cells express integrin receptors on the luminal aspect of their membrane.

  1992cited by this paper
• Expression of intercellular adhesion molecule-1 in atherosclerotic plaques.

  1992cited by this paper
• Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.

  1992cited by this paper
• Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages.

  1991cited by this paper
• Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III.

  1991cited by this paper
• Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel.

  1991cited by this paper
• GMP-140 mediates adhesion of stimulated platelets to neutrophils.

  1990cited by this paper
• Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion.

  1989cited by this paper
• Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils

  1989cited by this paper

• Current Strategies for Microbubble-Based Thrombus Targeting: Activation-Specific Epitopes and Small Molecular Ligands

  2021cites this paper
• Molecular imaging of arterial and venous thrombosis

  2020cites this paper
• Tirofiban, a Glycoprotein IIb/IIIa Antagonist, Has a Protective Effect on Decompression Sickness in Rats: Is the Crosstalk Between Platelet and Leukocytes Essential?

  2018cites this paper
• Molecular Imaging of Atherothrombotic Diseases: Seeing Is Believing.

  2017cites this paper
• Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice.

  2015cites this paper
• Complement and platelets: Mutual interference in the immune network.

  2015cites this paper
• The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow

  2015cites this paper
• Targeting platelet-neutrophil interactions in giant-cell arteritis.

  2014cites this paper
• Integrin &agr;IIb&bgr;3: From Discovery to Efficacious Therapeutic Target

  2013cites this paper
• Platelet I&kgr;B Kinase-&bgr; Deficiency Increases Mouse Arterial Neointima Formation via Delayed Glycoprotein Ib&agr; Shedding

  2013cites this paper
• Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex

  2013cites this paper
• Platelet-leukocyte crosstalk: Linking proinflammatory responses to procoagulant state.

  2013cites this paper
• The Potential of Monoclonal Antibodies to Reduce Reperfusion Injury in Myocardial Infarction

  2012cites this paper
• Apoptosis in the anucleate platelet.

  2012cites this paper
• Contemporary use of glycoprotein IIb/IIIa inhibitors

  2012cites this paper
• Novel Single-Chain Antibody-Targeted Microbubbles for Molecular Ultrasound Imaging of Thrombosis: Validation of a Unique Noninvasive Method for Rapid and Sensitive Detection of Thrombi and Monitoring of Success or Failure of Thrombolysis in Mice

  2012cites this paper
• Antiplatelet therapy in children: why so different from adults'?

  2012cites this paper
• Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin

  2010cites this paper
• Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting

  2009cites this paper
• Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability.

  2009cites this paper
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Platelet-neutrophil-interactions: linking hemostasis and inflammation.

  2007cites this paper
• Therapeutic Inhibitors of Platelet Aggregation – from Aspirin to Integrin Blockersf

  2007cites this paper
• Rationale for intracoronary administration of abciximab

  2007cites this paper
• Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.

  2006cites this paper
• Concentration-dependent effect of abciximab on platelets and neutrophils in a model of cardiopulmonary bypass

  2006cites this paper
• Antiplatelet therapy in children.

  2006cites this paper
• Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery Disease

  2005cites this paper
• Identity of the amino acid residues involved in C3bi binding to the I-domain supports a mosaic model to explain the broad ligand repertoire of integrin alpha M beta 2.

  2005cites this paper
• GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention

  2005cites this paper
• Procoagulant activity of adherent platelets

  2005cites this paper
• Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk.

  2005cites this paper
• Clopidogrel inhibits platelet-leukocyte adhesion and plateletdependent leukocyte activation

  2005cites this paper
• Improved blood compatibility of a stent graft by combining heparin coating and abciximab.

  2005cites this paper
• Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

  2004cites this paper
• Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non‐ST segment elevation myocardial infarction. What have we learned in the last 10 years?

  2004cites this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

  2004cites this paper
• Inflammation and Cardiovascular Risk: An Overview

  2004cites this paper
• A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic

  2004cites this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Chronic platelet and neutrophil adhesion: a causal role for neointimal hyperplasia in in-stent restenosis.

  2003cites this paper
• Chronic Platelet and Neutrophil Adhesion: A Causal Role for Neointimal Hyperplasia in In-Stent Restenosis

  2003cites this paper
• Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.

  2003cites this paper
• Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.

  2003cites this paper
• Comparative Pharmacology of GP IIb/IIIa Antagonists

  2003cites this paper
• Facilitated Primary Percutaneous Transluminal Coronary Angioplasty for Acute ST Segment Elevation Myocardial Infarction: Rationale for Reuniting Pharmacologic and Mechanical Revascularization Strategies

  2003cites this paper
• Platelets and anti-platelet therapy.

  2003cites this paper
• Role of P‐selectin, β2‐integrins, and Src tyrosine kinases in mouse neutrophil–platelet adhesion

  2003cites this paper
• Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates.

  2002cites this paper
• Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.

  2002cites this paper
• Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?

  2002cites this paper
• The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alphaMbeta2).

  2002cites this paper
• Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial.

  2002cites this paper
• Platelets: is aspirin sufficient or must we know how to pronounce abciximab?

  2002cites this paper
• Glycoprotein IIb/IIIa antagonists - from bench to practice

  2002cites this paper
• Plasminogen activators in inflammation and sepsis.

  2002cites this paper
• Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene.

  2002cites this paper
• Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?

  2002cites this paper
• Platelets Activated by Collagen Through Immunoreceptor Tyrosine-Based Activation Motif Play Pivotal Role in Initiation and Generation of Neointimal Hyperplasia After Vascular Injury

  2002cites this paper
• Anti-platelet Effects of GPIIb/IIIa and P-Selectin Antagonism, Platelet Activation, and Binding to Neutrophils

  2002cites this paper
• Pathophysiologie der Thrombozytenaktivierung und Pharmakolgie der GPIIb/IIIa-Inhibitoren

  2001cites this paper
• GPIIb-IIIa Receptor Inhibitors: What the Interventional Radiologist Needs to Know

  2001cites this paper
• Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin.

  2001cites this paper
• Integrin αMβ2-Mediated Cell Migration to Fibrinogen and Its Recognition Peptides

  2001cites this paper
• Interaction of Fibrin with VE‐Cadherin

  2001cites this paper
• &bgr;3-Integrin–Deficient Mice but Not P-Selectin–Deficient Mice Develop Intimal Hyperplasia After Vascular Injury: Correlation With Leukocyte Recruitment to Adherent Platelets 1 Hour After Injury

  2001cites this paper
• [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].

  2001cites this paper
• Platelet Function Inhibitors in the Year 2000

  2001cites this paper
• Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.

  2001cites this paper
• Novel platelet inhibitors.

  2001cites this paper
• Anti-GPIIb/IIIa Drugs: Current Strategies and Future Directions

  2001cites this paper
• Update on Strategies to Improve Thrombolysis for Acute Myocardial Infarction

  2001cites this paper
• c 7 E 3 Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen Implications for Myocardial Reperfusion Injury

  2000cites this paper
• Importance of microembolization and inflammation in atherosclerotic heart disease.

  2000cites this paper
• Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor).

  2000cites this paper
• IIb's are not IIb's.

  2000cites this paper
• c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen: Implications for Myocardial Reperfusion Injury

  2000cites this paper
• Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease.

  2000cites this paper
• Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.

  2000cites this paper
• From Discovery to Efficacious Therapeutic Target

  year unknowncites this paper